<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053088</url>
  </required_header>
  <id_info>
    <org_study_id>IPPM2019IMPACT</org_study_id>
    <nct_id>NCT04053088</nct_id>
  </id_info>
  <brief_title>SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Surgical Aortic Valve Replacement: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPACT Registry represents a non-interventional, prospective, open-label, multicenter,&#xD;
      international registry with a follow-up of 5 years that includes data of patients undergoing&#xD;
      aortic valve replacement with the Edwards INSPIRIS RESILIA Aortic Valve™. The IMPACT Registry&#xD;
      will be performed in up to 25 participating sites across Germany, Austria and Switzerland. A&#xD;
      minimum number of 500 patients (20 patients per center) will be enrolled. Patients will&#xD;
      undergo follow-up visits at baseline, surgery, pre-discharge, year 1, year 3 and year 5.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The INSPIRIS RESILIA Aortic Valve™ is a stented tri-leaflet valve comprised of bovine&#xD;
      pericardial tissue. The tissue is created by treating bovine pericardial tissue with Edwards&#xD;
      Integrity Preservation. It incorporates a stable capping anticalcification process, which&#xD;
      blocks residual aldehyde groups known to bind with calcium. Tissue preservation with glycerol&#xD;
      allows the valve to be stored without a traditional liquid-based solution, such as&#xD;
      glutaraldehyde. Therefore, valve is stored under dry packaging conditions and consequently&#xD;
      does not require rinsing prior to implantation.&#xD;
&#xD;
      The novel tissue preservation technology significantly improves hemodynamic and&#xD;
      anticalcification properties compared with the standard Perimount valve in an ovine model&#xD;
      (Flameng et al., 2015). The RESILIA tissue has been studied in the COMMENCE trial: Two year&#xD;
      data show that the NYHA class improved in 65.7% of patients, effective orifice area after&#xD;
      implantation was 1.6 ± 0.5 cm2; mean gradient was 10.1 ± 4.3 mmHg; and paravalvular leak was&#xD;
      none/trivial in 94.5% of patients (mild to moderate in 0.5%) (Puskas et al., 2017).&#xD;
&#xD;
      On the sizes 19 - 25 mm the INSPIRIS RESILIA Aortic Valve™ has been outfitted with the VFit&#xD;
      technology, which incorporates two novel features designed for potential future&#xD;
      valve-in-valve procedures: fluoroscopically visible size markers and an expandable cobalt&#xD;
      chromium alloy band. No clinical data are available that evaluate the use of the INSPIRIS&#xD;
      RESILIA Aortic Valve™ in patients to date.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 1 year</time_frame>
    <description>All-cause mortality after 1 year will be investigated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 3 years</time_frame>
    <description>All-cause mortality after 3 years will be investigated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 5 years</time_frame>
    <description>All-cause mortality after 5 years will be investigated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 1 year</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 3 years</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 5 years</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 1 year</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 3 years</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 5 years</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 1 year</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 3 years</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 5 years</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 1 year</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 3 years</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 5 years</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 1 year</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 3 years</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 5 years</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 1 year</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at baseline) will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 3 years</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at the preceding follow-up visit) will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 5 years</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at the preceding follow-up visit) will be documented and assessed</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>SAVR patients</arm_group_label>
    <description>patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INSPIRIS RESILIA Aortic Valve™</intervention_name>
    <description>Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™</description>
    <arm_group_label>SAVR patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Minimum of 500 patients (20 patients per center) undergoing Surgical Aortic Valve&#xD;
        Replacement (SAVR) using the INSPIRIS RESILIA aortic valve™ (all comers).&#xD;
&#xD;
        The required sample size was calculated using the online calculator at&#xD;
        http://www.surveysystem.com/sscalc.htm. It was estimated, from the COMMENCE Trial dataset&#xD;
        (Puskas et al., 2017) that all-cause mortality is around 1.2% at year 1 and 2.0% at year 2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is at least 18 years old&#xD;
&#xD;
          2. Patient has an aortic valve vitium and requires an aortic valve replacement with the&#xD;
             Edwards INSPIRIS RESILIA Aortic Valve™&#xD;
&#xD;
          3. Patient is scheduled to attend yearly follow-up visits at the registry center up to 5&#xD;
             years&#xD;
&#xD;
          4. Patient provides written informed consent prior to the procedure and in case of&#xD;
             emergency after the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Disability and / or other circumstances under which the patient is not capable to&#xD;
             understand the nature, significance and scope of the clinical trial&#xD;
&#xD;
          2. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to&#xD;
             the scheduled aortic valve replacement surgery&#xD;
&#xD;
          3. Patient has a life expectancy ≤ 12 months for any reason&#xD;
&#xD;
          4. Valve implantation is not possible in accordance with the device IFU&#xD;
&#xD;
          5. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Bakhtiary, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinik Siegburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Zierer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kepler University Hosiptal Linz and Hospital Wels-Grieskirchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Botta, PhD</last_name>
    <phone>+4944718503325</phone>
    <email>beate.botta@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Lueske, PhD</last_name>
    <phone>+4944718503324</phone>
    <email>claudia.lueske@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck, Uniklinik für Herzchirurgie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaos Bonaros, Prof. Dr.</last_name>
      <email>nikolaos.bonaros@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Lucas Stastny, MD</last_name>
      <email>lukas.stastny@tirol-kliniken.at</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolaos Bonaros, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Stastny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Zierer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>• Universitätsklinikum Salzburg, Herzchirurgie, Gefäßchirurgie und endovaskuläre Chirurgie</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Vötsch, Prof. Dr.</last_name>
      <email>andreas.zierer@kepleruniklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Andreas Vötsch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>• Klinikum Wels-Grieskirchen, Herz-, Gefäß- und Thoraxchirurgie</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Zierer, Prof. Dr.</last_name>
      <email>andreas.zierer@kepleruniklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Hans J Geissler, Prof. Dr.</last_name>
      <email>hansjoachim.Geissler@klinikum-wegr.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pollari, PD MD</last_name>
      <email>francesco.pollari@klinikum-nuernberg.de</email>
    </contact>
    <investigator>
      <last_name>Francesco Pollari, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau/Universität Regensburg</name>
      <address>
        <city>Passau</city>
        <state>Bayern</state>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parwis Massoudy, Prof. Dr.</last_name>
      <email>parwis.massoudy@klinikum-passau.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Czesla, MD</last_name>
      <email>markus.czesla@klinikum-passau.de</email>
    </contact_backup>
    <investigator>
      <last_name>Parwis Massoudy, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Czesla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Leyh, Prof. Dr.</last_name>
      <email>leyh_r@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Seymur Karimli, MD</last_name>
      <email>karimli_s@ukw.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>• Universitätsklinikum Frankfurt, Thorax-, Herz- und thorakale Gefässchirurgie</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Walter, Prof. Dr.</last_name>
      <email>thomas.walther@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Walter, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Herzchirurgie</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Dewald, Prof. Dr.</last_name>
      <email>dewald.oliver@klinikum-oldenburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Fritz Mellert, PD MD</last_name>
      <email>mellert.fritz@klinikum-oldenburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver Dewald, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fritz Mellert, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Autschbach Rüdiger, Prof. Dr.</last_name>
      <email>rautschbach@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ali Aljalloud, MD</last_name>
      <email>aaljalloud@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rüdiger Autschbach, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Aljalloud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schüchtermann Klinik</name>
      <address>
        <city>Bad Rothenfelde</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Doll, Prof. Dr.</last_name>
      <email>ndoll@schuechtermann-klinik.de</email>
    </contact>
    <investigator>
      <last_name>Nicolas Doll, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justus Strauch, Prof. Dr.</last_name>
      <email>justus.strauch@bergmannsheil.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Schlömicher, MD</last_name>
      <email>markus.schloemicher@bergmannsheil.de</email>
    </contact_backup>
    <investigator>
      <last_name>Justus Strauch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Schlömischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Herzchirurgie UKD</name>
      <address>
        <city>Düsseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Artur Lichtenberg, Prof. Dr.</last_name>
      <email>artur.lichtenberg@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Arash Mehdiani, MD</last_name>
      <email>arash.mehdiani@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Artur Lichtenberg, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arashq Mehdiani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjang Ruhpawar, Prof. Dr.</last_name>
      <email>arjang.ruhparwar@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Wendt, Prof. Dr.</last_name>
      <email>daniel.wendt@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Kamler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arjang Ruhpawar, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Wendt, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>• Universitätsklinikum Leipzig, Thorax- und Kardiovaskuläre Chirurgie</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Borger, Prof. Dr.</last_name>
      <email>christian.hagl@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Michael Borger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BundeswehrKrankenhaus Klinik XVII und XVIII</name>
      <address>
        <city>Koblenz</city>
        <zip>56072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Feyrer, Prof. D.</last_name>
      <email>richardfeyrer@bundeswehr.org</email>
    </contact>
    <investigator>
      <last_name>Richardf Feyrer, Prof. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Bakhtiary, Prof. Dr.</last_name>
      <email>farhad.bakhtiary@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89091</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Liebold, Prof. Dr.</last_name>
      <email>andreas.liebold@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Liebold, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Bakhtiary, Prof. Dr.</last_name>
      <email>farhad.bakhtiary@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis, Catharina Hart- en Vaatcentrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ka Yan Lam, MD</last_name>
      <email>kayan.lam@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Ka Yan Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HerzKlinik Hirslanden, Herz- und thorakale Gefässchirurgie</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürg Grünenfelder, Prof. Dr.</last_name>
      <email>juerg.gruenenfelder@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Jürg Grünenfelder, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HerzZentrum Hirslanden, Herz- und Gefässchirurgie</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Weber, PD MD</last_name>
      <email>weber@herzzentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Alberto Weber, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Salaun E, Clavel MA, Rodés-Cabau J, Pibarot P. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation. Heart. 2018 Aug;104(16):1323-1332. doi: 10.1136/heartjnl-2017-311582. Epub 2018 May 7. Review.</citation>
    <PMID>29735584</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical Aortic Valve Replacement (SAVR)</keyword>
  <keyword>INSPIRIS RESILIA</keyword>
  <keyword>Durability</keyword>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

